CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Late breaking results of the Canadian Cancer Trials Group (CCTG) BR31 study “A double-blind, placebo-controlled, randomized phase 3 trial of adjuvant durvalumab in completely resected non-small-cell lung cancer” were presented at the European Society for Medical Oncology (ESMO) Congress 2024.
The GA1 TOPGEAR trial results were presented at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain and simultaneously published in the
It is with great sadness that we say goodbye to our highly respected patient representative David McMullen. He has been a CCTG patient representative since 2015 and an outstanding patient advocate with numerous organizations, including Myeloma Canada and the Canadian Myeloma Research Group.
Kinetic profiling of RAS mutations with circulating tumor DNA - CO26
Purpose: In metastatic colorectal cancer (mCRC), RAS mutations drive resistance to anti-epidermal growth factor receptor antibodies. It is unclear whether RAS mutations ever become clonally undetectable.
The Canadian led HE1 trial results, published in Lancet Oncology, confirm the quality-of-life benefits of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver meta
The CCTG NE2 STOPNET neuroendocrine study has officially open in Canada. Researchers are investigating whether somatostatin analogues (SSA) are needed after targeted therapy for patients with neuroendocrine tumours.
“NE2 addresses an important question for patients and the healthcare system of whether we can reduce treatment burden by stopping SSAs after PRRT has been completed,” says Dr Jonathan Loree, the NE2 study co-chair and BC Cancer Oncologist.
